SCHEMBL6500801

SCHEMBL6500801

CCN(C(=O)OC(C)(C)C)c1ccc(Cn2c(C)nc3ccc(C(=O)O)nc32)c(Cl)c1

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.39
MAPT P10636 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
KDM4E B2RXH2 2/20 0.36
HSD17B10 Q99714 2/20 0.36
HPGD P15428 1/20 0.36
HTT P42858 1/20 0.36
PPARG P37231 2/20 0.35
GLP1R P43220 6/20 0.33
KMT2A Q03164 1/20 0.32
PIK3CB P42338 2/20 0.31
RORC P51449 1/20 0.31
LMNA P02545 1/20 0.31
MAPK1 P28482 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
NPC1 O15118 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6502447 0.92 MAPT (0.38) ALDH1A1MAPTSMN1; SMN2KDM4EHSD17B10
SCHEMBL6503105 0.90 ALDH1A1 (0.38) ALDH1A1MAPTSMN1; SMN2KDM4EHSD17B10
SCHEMBL6492876 0.87 GLP1R (0.34) ALDH1A1MAPTSMN1; SMN2KDM4EHSD17B10
SCHEMBL6499909 0.87 PIK3CB (0.36) ALDH1A1MAPTSMN1; SMN2KDM4EHSD17B10
SCHEMBL6491710 0.85 PPARG (0.37) ALDH1A1MAPTSMN1; SMN2KDM4EHSD17B10
SCHEMBL6493526 0.84 PPARG (0.52) PPARG
SCHEMBL6500411 0.82 ALDH1A1 (0.38) ALDH1A1MAPTSMN1; SMN2KDM4EHSD17B10
SCHEMBL6305870 0.82 ALDH1A1 (0.41) ALDH1A1MAPTSMN1; SMN2KDM4EHSD17B10
SCHEMBL6491707 0.82 ALDH1A1 (0.40) ALDH1A1MAPTSMN1; SMN2KDM4EHSD17B10
SCHEMBL6493261 0.82 MAPT (0.37) ALDH1A1MAPTSMN1; SMN2KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6890934-B2 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-05-10 US disclosed
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-09-11 US disclosed
US-6573274-B1 Treatment of the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-06-03 US disclosed
EP-1136492-A1 SULFONAMIDE COMPOUNDS AND USES THEREOF AS MEDICINES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-09-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines PDE2A, PDE3A, PDE5A ALDH1A1 476/4885MAPT 4144/4885SMN1; SMN2 325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.